Substituted diazenylanilines as fluorescence quenchers and their uses.
Patent Information
- Application Number
- JP2024527773
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-23
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-11-23
AI Technical Summary
【0086】 本発明の利点 本発明は、励起状態エネルギーの優れた非蛍光消光剤ファミリーを提供するものであり、既知のBHQ-2(「ブラックホール消光剤」)の十分に規定された改変消光剤である。文献によれば、BHQ-2は、可視領域の橙色から赤色部分(560~670nm)で発光する色素に適しているが、FAMには適さない。FAMには、BHQ-1を使用するのが好ましい。本発明は、プローブ成分に迅速に結合できるように官能化されたユニバーサルな消光剤類を提供し、また可視スペクトル全範囲をカバーする所望の広い消光範囲を有するように設計された消光剤を提供する。本発明は、室温で安定であり、かつ本質的に非吸湿性の蛍光色素のアジドの使用を説明する。
Smart Images

Figure 2024542435000019 
Figure 2024542435000020 
Figure 2024542435000021
Abstract
Description
[Technical field]
[0001] The present invention relates to a fluorescence quencher. In particular, the present invention relates to substituted diazenylanilines, as well as their nucleic acid conjugates, complexes and salts, which can be used as fluorescence quenchers in chemical and biological sciences, such as cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications. The present invention also relates to the synthesis of substituted diazenylanilines, as well as their nucleic acid conjugates, complexes and salts. More specifically, the present invention relates to 2,2'-((4-((2,5-disubstituted-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-2 / 3-substituted phenyl)azanediyl)dialkanols, and the preparation method of said compounds, as well as the use of said compounds as fluorescence quenchers in cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications. [Background technology]
[0002] The development of cost-effective technologies to detect and quantify chemical and biological substances has widely promoted advanced innovation in the pharmaceutical, diagnostic and instrumentation fields. It has become one of the major fields for identifying substances from the microscopic level to whole peptides, proteins, nucleic acids and other medicamentously important substances. These studies are intricately intertwined with our lives as they play a key role in identifying diseases and at the same time can help detect and / or quantify biologically important entities.
[0003] The method of identifying diagnostically useful analytes is based on a specific set of their unique characteristics that bind in chemical and biological environments. So far, there are many binding methods, such as antigen-antibody interaction, protein-enzyme interaction, nucleic acid modification system (Northern blotting) and labeling technology. A variety of labels have been developed to label oligonucleotides quickly and efficiently on the bench, and these methods are useful not only when making small amounts of detection probes, but also when mutation analysis is required.
[0004] Labels that can be detected using fluorescence spectroscopy are of great interest because their synthesis is tunable. They can be derivatized by simply introducing different groups, creating a wide variety of fluorescent labels corresponding to different kinds of moieties. Moreover, they are readily commercially available. This method, based on the ability of fluorescent compounds to transfer the energy absorbed from light to nearby molecules, has been exploited to develop homogeneous methods of nucleic acid detection.
[0005] To achieve a robust, sensitive, and sufficiently specific real-time nucleic acid amplification assay, it is essential to use an appropriate fluorescent dye and quencher label pair, including the type of hybridization probe used in the assay and the number of targets to be detected.
[0006] In their excited state, fluorescent dyes can lose excitation energy in several ways, besides releasing photon energy. This fluorescence quenching can occur through molecular motion (dynamic quenching), excited state complex formation with other substances (photoquenching), contact quenching (static quenching) or energy transfer to another molecule (fluorescence resonance energy transfer or FRET). Many nucleic acid fluorescence detection techniques use fluorescently labeled probes that function by quenching the fluorescence of a neighboring second fluorescent label, or use a fluorescence-quencher pair. A probe dual-labeled with a reporter dye and a quencher dye measures the change in its fluorescence to monitor any biochemical events. These events cause a change in the distance between the reporter and the quencher, which results in an observed change in fluorescence (Non-Patent Document 1).
[0007] Real-time nucleic acid amplification assays have a superior ability to obtain better qualitative and quantitative results. Moreover, these assays can be performed in sealed tubes, thus avoiding contamination. Fluorescent nucleic acid hybridization probes contain various pairs of coordinating fluorescent dyes and quenchers. Some methods are based on pairs of complementary oligodeoxyribonucleotides, one of which remains as a probe for the single-stranded target sequence. The 5' end of one oligodeoxyribonucleotide is labeled with a donor fluorescent dye, and the 3' end of the other oligodeoxyribonucleotide is labeled with an acceptor fluorescent dye (Non-Patent Document 2).
[0008] One important application of probes containing reporter-quencher molecule pairs is their use in nucleic acid amplification reactions, such as the polymerase chain reaction (PCR), to detect the presence and amplification of target nucleic acid sequences (Non-Patent Document 3).
[0009] In TaqMan assays, the efficiency of energy transfer decreases with inverse sixth power of the distance between the reporter and quencher, so for the assay, the donor and quencher are preferably located at the 3'-end and 5'-end of the probe. Therefore, if the quencher is not close enough to the reporter to achieve the most efficient quenching, the background emission from the probe may be very high (Non-Patent Document 4).
[0010] Fluorescence-quencher linear pair probes are standard tools in real-time PCR and their strong signal-to-noise ratio, low cost and compatibility with different PCR techniques make them ideal as industrial marker standards for gene quantification in a wide range of applications. Black hole quencher dyes BHQ0, BHQ1, BHQ2 and BHQ3 are used to quench across the entire visible spectrum. FAM and BHQ dyes have shown top-class performance as reviewed in various scientific reports. TaqMan probes are used for quantitative real-time PCR analysis of gene expression, which includes PCR primers and TaqMan probes with dye labels (FAM) at the 5' end, minor groove binders (MGB) and non-fluorescent quenchers (NFQ) / dark quenchers at the 3' end. BHQ-1 is used to quench green and yellow dyes such as FAM, TET and HEX. BHQ-2 and BHQ-3 have been reported to be used to quench orange or red dyes such as TAMRA, Texas Red and Cy5. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Chem. Commun., 2010, 46, 8154-8156 [Non-Patent Document 2] Nucleic Acids Research, 2002, Vol.30 No.21 e122 [Non-Patent Document 3] Acc. Chem. Res. 2011, 44, 2, 83-90 [Non-Patent Document 4] Nucleic Acids Res. 2011, 39, e112 Summary of the Invention
[0012] Object of the Invention The main object of the present invention is to provide substituted diazenylanilines and their nucleic acid conjugates, complexes and salts, which can potentially be used as fluorescence quenchers in chemical and biological sciences such as cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications.
[0013] Another object of the present invention is to provide methods for the preparation of substituted diazenylanilines, and their nucleic acid conjugates, complexes and salts.
[0014] Yet another object of the present invention is to use the substituted diazenylanilines, and their nucleic acid conjugates, complexes and salts in chemical and biological sciences such as cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications.
[0015] Summary of the Invention Thus, the present invention relates to substituted diazenylanilines that can potentially be used as fluorescence quenchers in chemical and biological sciences such as cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications, their synthesis and fluorescence quenching properties studies, their nucleic acid conjugates, complexes and salts, as well as methods for preparing said novel compounds.
[0016] Thus, the present invention relates to compounds of general formula I: [ka] [In the formula, R is independently selected from the group consisting of hydrogen and halogen; R1 and R2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted (C1-C4) alkyl and (C1-C6) alkoxy; R3 is selected from the group consisting of hydroxy, halogen, (C1-C6)alkoxy, substituted or unsubstituted (C1-C4)alkyl, thioalkyl(S C1-C6), methylamino and dimethylamino; R4 is selected from the group consisting of hydrogen, hydroxy, halogen, (C1-C6)alkoxy, and substituted or unsubstituted (C1-C4)alkyl; m and n are selected from 0 to 3; Y1 and Y2 are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, glycol, substituted or unsubstituted alkylaryl, oxoalkanoic acid, epoxy, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, acid halide, acylimidazole, thioester, p-nitrophenyl ester, alkyl ester, mononucleotide unit, two or more mononucleotide units with or without separate phosphate or polyphosphate groups linked by a nucleoside group. The present invention provides compounds of the formula:
[0017] In a preferred embodiment of the invention, the compound of formula I is selected from the following group: TIFF2024542435000002.tif212160
[0018] The present invention also provides a process for the preparation of compounds of general formula I, in which R, R1, R2, R3, R4, m, n, Y1 and Y2 are as defined above, and nucleic acid conjugates, complexes and salts thereof, comprising the steps of: [ka] a. reacting a solution of unsubstituted or substituted 4-nitroaniline in HCl with a solution of sodium nitrite in distilled water at 0° C. to form a diazonium salt, which is then reacted with a substituted aniline to form a compound of formula S1; b. reacting the substituted aniline mixture with a substituted alkyl halide in the presence of a base to form a compound of formula S2; c. reacting the compound of formula S1 in HCl with sodium nitrite solution to form a diazonium salt, which is then reacted with the compound of formula S-2 in the presence of NaOAc buffer to obtain a compound having the general formula I; and d. isolating the compound of formula I from the reaction mixture and purifying it by washing with an organic solvent or by chromatography; The present invention provides a method of manufacturing the same.
[0019] In a preferred embodiment of the present invention, steps a to c of the above-mentioned method are carried out in the presence of an organic solvent selected from CH3CN, dimethylsulfoxide, water and tetrahydrofuran at a temperature range of 0°C to 100°C for 1 minute to 3 days. [ka] a) reacting compound S2 (Y1, Y2=OH, and m, n=1) in dry DCM with DMT-Cl in the presence of a base (DIPEA) at room temperature under an inert atmosphere to give compound S3; b) reacting S3 with succinic anhydride and DMAP in an organic solvent for 12-48 hours to obtain compound S4; and c) reacting the diazonium salt of S1 with S4 to obtain a compound having general formula I; The present invention provides a method comprising:
[0020] The present invention also relates to a method for producing a method for manufacturing a semiconductor device comprising the steps of: [ka] a. coupling a compound of formula S4 with an amine functional group of a solid support CPG bead of formula S5 to generate S6, followed by deprotection of the DMT group to obtain S7; b. reacting S7 with a nucleotide phosphoramidite to form oligonucleotide S8, which is then 5'-modified with a hexynyl phosphoramidite to give product S9; c. treating S9 with a base to cleave the oligonucleotide from the solid support to obtain S10; and d. reacting S10 with an azide of a fluorescent dye to obtain an oligonucleotide probe of general formula S12; The present invention provides a method for preparing a conjugate compound of general formula I, wherein Q is a compound of formula 1, comprising:
[0021] The present invention provides compounds of general formula I that are useful in the analysis of nucleic acids (DNA, RNA), peptides, chemicals, pharmaceuticals, microorganisms and other biological substances of diagnostic importance.
[0022] The present invention provides compounds of general formula I that are useful in the development of diagnostic kits for the detection of substances, hormones, pathogenic microorganisms and viruses, antibodies, as well as enzymes and nucleic acids, particularly those involved in disease states.
[0023] The present invention provides compounds of general formula I, which are useful for the manufacture of fluorescent probes, tags, markers, diagnostics, ion sensors, pharmaceuticals for detecting / capturing ions in fluorescence-based imaging and / or analysis of cells, body fluids, chemical mixtures and / or other useful applications.
[0024] The invention also provides compositions of compounds of general formula I with acetyl, azide, n-hydroxysuccinimide, oxoalkanoic acid, glycolate, thiol, amine, hydroxide, maleimide, tetrazine, phosphate, sodium salt, potassium salt, or phosphoramidite.
[0025] In a preferred embodiment of the present invention, the compounds of general formula I are useful for preparing dual-labeled probes and for their single, double and multiplex analysis in RT-PCR or other related detection systems.
[0026] In one embodiment of the invention, the compounds are useful as fluorescence quenchers in the chemical and biological sciences.
[0027] In another embodiment of the present invention, the compounds exhibit a broad extinction range between 450 nm and 700 nm.
[0028] Additionally, the present invention provides compounds having general formula I that can potentially be used as fluorescence quenchers in chemical and biological sciences, such as cell imaging applications, fluorescent and non-fluorescent tags, and other useful biological applications (e.g., development of diagnostic kits, etc.). [Brief description of the drawings]
[0029] The following drawings form part of the present specification and are included to further explain aspects of the present disclosure. The present disclosure may be better understood by reference to the drawings in combination with the detailed description of specific embodiments presented herein: [Figure 1] FIG. 1 shows the absorption spectra of newly synthesized quencher derivatives (1-9) according to an embodiment of the present disclosure. [Diagram 2] FIG. 2 shows a comparison of the absorption of BHQ-2 and CDRI-Q2 at 20 μM concentration in PCR buffer according to an embodiment of the present disclosure. [Diagram 3] FIG. 3 shows the fluorescence quenching of 5-FAM in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Figure 4] FIG. 4 shows the fluorescence quenching of CY3 in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Diagram 5]FIG. 5 shows the fluorescence quenching of 5-TAMRA in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Figure 6] FIG. 6 shows the fluorescence quenching of CalFluor in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Figure 7] FIG. 7 shows the fluorescence quenching of Texas Red in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Figure 8] FIG. 8 shows the fluorescence quenching of Cy5 in the presence of various concentrations of CDRI Q2(1) in PCR buffer according to an embodiment of the present disclosure. [Figure 9] FIG. 9 shows RT-PCR data with cycle threshold (Ct) on the X-axis and RFU on the Y-axis according to an embodiment of the present disclosure. [Figure 10] FIG. 10 shows multiplex RT-PCR detection of SARS-CoV-2 viral genes E and RdRp with positive controls and RnaseP as a housekeeping gene according to an embodiment of the present disclosure, with data representing cycle threshold (Ct) on the X-axis and RFU on the Y-axis. [Figure 11] FIG. 11 shows multiplex RT-PCR detection of SARS-CoV-2 viral genes E and RdRp and RnaseP as a housekeeping gene using a positive RNA sample from a COVID-19 positive patient according to an embodiment of the present disclosure; data represents cycle threshold (Ct) on the X-axis and RFU on the Y-axis.
[0030] (abbreviation) PCR Polymerase Chain Reaction TDW Triple distilled water
[0031] Detailed Description of the Invention Those skilled in the art will recognize that the present disclosure is subject to variations and modifications other than those specifically described. It should be understood that the present disclosure includes all such variations and modifications. The present disclosure also includes all such steps, features, compositions and compounds mentioned or shown herein, individually or collectively, and also includes any and all combinations of any one or more of the steps or features.
[0032] The present invention will now be described in detail with reference to certain preferred and optional embodiments so that its various aspects may be more fully understood and appreciated.
[0033] For convenience, before further description of the present disclosure, certain terms and examples used herein are explained here. These definitions should be read in light of the rest of the present disclosure and understood by those skilled in the art. Terms used herein have meanings that are recognized and known to those skilled in the art, but for convenience and completeness, certain terms and their meanings are provided below.
[0034] (definition) The articles "a", "an" and "the" are used to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article.
[0035] The terms "comprise" and "comprising" are used in an inclusive and open sense, meaning that additional elements may be included. The term is not intended to be interpreted as "consisting only of."
[0036] Throughout this specification, unless the context indicates otherwise, the word "comprises" and variations such as "comprises" and "comprising" are understood to mean the inclusion of a stated element or step, or group of elements and steps, but not the exclusion of other elements or steps, or group of elements or steps.
[0037] Thus, the present invention relates to substituted diazenylanilines, which can potentially be used as fluorescence quenchers in chemical and biological sciences such as cell imaging applications, diagnostic methods, fluorescent tags, non-fluorescent tags, pharmaceuticals and other useful applications, as well as to the synthesis and study of fluorescence quenching properties of their nucleotide conjugates, complexes and salts, and methods for the preparation of said novel compounds.
[0038] The term "quencher probe" refers to a quencher that can be used to quench and / or reduce fluorescence emissions in various UV-Visible regions in response to a particular analyte / substance.
[0039] The present invention relates to a compound of formula I: [ka] [In the formula, R is selected from the group consisting of hydrogen and halogen; R1 and R2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted (C1-C4) alkyl and (C1-C6) alkoxy; R3 is selected from the group consisting of hydroxy, halogen, (C1-C6)alkoxy, substituted or unsubstituted (C1-C4)alkyl, thioalkyl(SC1-C6), methylamino and dimethylamino; R4 is selected from the group consisting of hydrogen, hydroxy, halogen, (C1-C6)alkoxy, and substituted or unsubstituted (C1-C4)alkyl; m and n are numbers independently selected from 0 to 3; Y1 and Y2 are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, glycol, substituted or unsubstituted alkylaryl, oxoalkanoic acid, epoxy, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, acid halide, acylimidazole, thioester, p-nitrophenyl ester, alkyl ester, phosphoramidite, mononucleotide unit, and two or more mononucleotide units with or without separate phosphate or polyphosphate groups linked by a nucleoside group. The present invention provides a compound of the formula:
[0040] Below is a list of representative substituted diazenylaniline compounds: TIFF2024542435000007.tif212160
[0041] Formula I (where R, R1, R2, R 3、 A method for preparing a compound of formula (wherein R4, m, n, Y1 and Y2 are as defined above) is shown in Scheme I. [ka]
[0042] The method comprises the steps of: a. reacting a solution of unsubstituted or substituted 4-nitroaniline in HCl with a solution of sodium nitrite in distilled water at 0° C. to form a diazonium salt, which is then reacted with a substituted aniline to form a compound having the general formula S1; b. reacting the substituted aniline mixture with a substituted alkyl halide in the presence of a base to form a compound having the general formula S2; c. reacting a compound of general formula S1 in HCl with sodium nitrite solution to form a diazonium salt, which is then reacted with a compound of general formula S-2 in the presence of NaOAc buffer to obtain a compound having general formula I; and d. Isolating the compound of general formula I from the reaction mixture and washing with an organic solvent or purifying it by chromatographic techniques.
[0043] The reactions are carried out in common organic solvents, especially CH3CN, dimethylsulfoxide, water and tetrahydrofuran, at temperatures ranging from 0°C to 100°C for 1 minute to 3 days depending on the reactants.
[0044] In another embodiment, the present invention provides a method for preparing a preferred compound having formula I (wherein R1, R2, R3 and R4 are as defined above; Y1, Y2=OH, m, n=1), which is shown in Scheme II. [ka]
[0045] The method comprises the steps of: a) reacting a solution of unsubstituted or substituted 4-nitroaniline in HCl with a solution of sodium nitrite in distilled water at 0° C. to form a diazonium salt, which is then reacted with a substituted aniline to form a compound having the general formula S1; b) reacting a compound having general formula S2 (wherein Y1, Y2 = OH and m, n = 1) in dry DCM with DMT-Cl in the presence of a base (DIPEA) at room temperature under inert atmosphere to obtain product S3; c) reacting the compound of formula S3 with succinic anhydride and DMAP in an organic solvent for 12 to 48 hours to obtain compound S4; d) reacting a compound of general formula S1 in HCl with sodium nitrite solution to form a diazonium salt, which is then reacted with a compound having general formula S4 in the presence of a buffer (NaOAc) to obtain a compound having general formula I; and e) isolating the compound of general formula I from the reaction mixture and washing it with an organic solvent or purifying it by chromatographic techniques.
[0046] The reactions are carried out in common organic solvents, especially CH3CN, dimethylsulfoxide, water and tetrahydrofuran, in the presence of buffer solutions at temperatures ranging from 0°C to 100°C for 1 minute to 3 days depending on the reactants.
[0047] In one embodiment of the invention, the compounds are useful as fluorescence quenchers in the chemical and biological sciences.
[0048] In another embodiment of the present invention, the compounds exhibit a broad extinction range between 450 nm and 700 nm.
[0049] Additionally, compounds having general formula I can potentially be used as fluorescence quenchers in chemical and biological sciences, such as in cell imaging applications, fluorescent and non-fluorescent tags, and other useful biological applications (e.g., development of diagnostic kits). EXAMPLES
[0050] The following examples are offered for illustrative purposes and are not intended to be limiting of the invention.
[0051] Example 1 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methoxyphenyl)azanediyl)bis(ethan-1-ol) (1) (CDRI-Q2) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R3 = OCH3, R4 = H) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP = 205-206 °C, MS (ESI) m / z 525 [M+H] +, 1H NMR (400 MHz, DMSO-d6) δ 8.47 - 8.40 (m, 2H), 8.09 - 8.03 (m, 2H), 7.62 (d, J = 9.3 Hz, 1H), 7.44 (s, 1H), 7.28 (s, 1H), 6.48 (dd, J = 9.4, 2.5 Hz, 1H), 6.40 (d, J = 2.5 Hz, 1H), 5.03 - 4.80 (m, 2H), 3.99 (s, 3H), 3.97 (s, 3H), 3.94 (s, 3H), 3.68 - 3.57 (m, 8H). 13C NMR (101 MHz, DMSO) δ 160.61, 156.28, 154.27, 153.76, 150.62, 148.44, 147.60, 141.34, 134.36, 125.57, 123.88, 118.66, 105.80, 101.37, 100.20, 95.24, 79.64, 58.81, 56.98, 56.80, 56.49, 53.93.
[0052] Example 2 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-ethoxyphenyl)azanediyl)bis(ethan-1-ol) (2) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=OCH2CH3) in ACN was slowly added at 0° C. After addition, the reaction mixture was stirred at 0° C. for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-ethoxyphenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 202~203 ℃, MS (ESI) m / z 539 [M+H] +, 1H NMR (400 MHz, DMSO-d6) δ 8.43 (d, J = 8.6 Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 9.3 Hz, 1H), 7.44 (s, 1H), 7.35 (s, 1H), 6.49 (d, J = 9.4 Hz, 1H), 6.44 - 6.35 (m, 1H), 4.88 (t, J = 5.1 Hz, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.98 (s, 3H), 3.94 (s, 3H), 3.68 - 3.56 (m, 8H), 1.44 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 160.12, 156.28, 154.25, 153.70, 150.63, 148.43, 147.58, 141.26, 134.36, 125.57, 123.88, 118.51, 106.06, 101.24, 100.27, 96.67, 65.10, 58.80, 56.81, 56.67, 53.91, 15.17.
[0053] Example 3 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-propoxyphenyl)azanediyl)bis(ethan-1-ol) (3) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=OCH2CH2CH3) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-propoxyphenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 202-203 °C, MS (ESI) m / z 553 [M+H] +, 1H NMR (400 MHz, DMSO-d6) δ 8.41 (d, J = 8.6 Hz, 2H), 8.11-7.90 (m, 2H), 7.62 (s, 1H), 7.45-7.19 (m, 2H), 6.74 - 6.31 (m, 2H), 4.41-4.11 (m, 2H), 4.10 - 3.59 (m, 16H), 1.92-1.80 (m, 2H), 1.19-1.02 (m, 3H).
[0054] Example 4 2,2'-((3-butoxy-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) (4) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=OCH2CH2CH2CH3) in ACN was slowly added at 0° C. After addition, the reaction mixture was stirred at 0° C. for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((3-butoxy-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MS (ESI) m / z 567 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 8.4 Hz, 2H), 8.10-7.90 (m, 2H), 7.61 (s, 1H), 7.79-7.22 (m, 2H), 6.77 - 6.22 (m, 2H), 4.12-3.64 (m, 2H), 4.12 - 3.64 (m, 16H), 2.01-1.75 (m, 2H), 1.67-1.46 (m, 2H), 1.12-0.88 (m, 3H).
[0055] Example 5 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-(hexyloxy)phenyl)azanediyl)bis(ethan-1-ol) (5) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=OCH2CH2CH2CH2CH2CH3) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-(hexyloxy)phenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 198-199 °C, MS (ESI) m / z 595 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.41 (d, J = 8.5 Hz, 2H), 8.11-7.92 (m, 2H), 7.68-7.53 (m, 1H), 7.45-7.21 (m, 2H), 6.75 - 6.30 (m, 2H), 4.47-4.11 (m, 2H), 4.08-3.60 (m, 16H), 1.99-1.76 (m, 2H), 1.63 - 1.44 (m, 2H), 1.40-1.27 (m, 4H), 0.87 (t, J = 6.5 Hz, 3H).
[0056] Example 6 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methylphenyl)azanediyl)bis(ethan-1-ol) (6) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=CH3) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to obtain the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methylphenyl)azanediyl)-bis(ethan-1-ol) as a purple solid. MP= 201-202 °C, MS (ESI) m / z 509 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.48 - 8.39 (m, 2H), 8.10 - 8.01 (m, 2H), 7.64 (d, J = 9.9 Hz, 1H), 7.44 (s, 1H), 7.37 (s, 1H), 6.75-6.69 (m, 2H), 4.86 (t, J = 5.2 Hz, 2H), 4.00 (s, 3H), 3.95 (s, 3H), 3.65-3.55 (m, 8H), 2.67 (s, 3H). 13C NMR (101 MHz, DMSO) δ 156.22, 153.67, 152.25, 150.76, 148.49, 147.24, 142.54, 142.25, 141.54, 125.57, 123.91, 118.02, 112.68, 110.76, 101.35, 100.35, 58.72, 56.84, 56.80, 53.73, 18.48.
[0057] Example 7 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-2,5-dimethoxyphenyl)azanediyl)bis(ethan-1-ol) (7) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R3=OCH3, R4=OCH3) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-2,5-dimethoxyphenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP=230-231 °C, MS (ESI) m / z 555 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.8 Hz, 2H), 8.00 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 9.2 Hz, 1H), 7.53(s, 1H), 7.4 (s, 1H), 7.0 (d, J = 2.34 Hz, 1H), 6.66 (dd, J = 2.4, 9.2Hz, 1H), 4.03 (s, 3H), 4.0 (s, 3H), 3.85 (s, 3H), 3.75 (s, 3H), 3.52 (t, J = 4.95 Hz, 4H), 3.23 (t, J = 4.96 Hz, 4H).
[0058] Example 8 2,2'-((3-bromo-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) (8) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R4=H, R3=Br) in ACN was slowly added at 0° C. After addition, the reaction mixture was stirred at 0° C. for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give the product 2,2'-((3-bromo-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 220-221° C., MS (ESI) m / z 573 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.8 Hz, 2H), 8.00 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 9.2 Hz, 1H), 7.53(s, 1H), 7.4 (s, 1H), 7.0 (d, J= 2.34 Hz, 1H), 6.66 (dd, J= 2.4, 9.2Hz, 1H), 4.03 (s, 3H), 4.0 (s, 3H), 3.82 (t, J= 4.95 Hz, 4H), 3.63 (t, J= 4.96 Hz, 4H).
[0059] Example 9 2,2'-((4-((4-((2,6-dichloro-4-nitrophenyl)diazenyl)-2,5-dimethoxyphenyl)diazenyl)-3-methoxyphenyl)azanediyl)bis(ethan-1-ol) (9) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R3=OCH3, R4=H) in ACN was slowly added at 0 °C. After addition, the reaction mixture was stirred at 0 °C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give 2,2'-((4-((4-((2,6-dichloro-4-nitrophenyl)diazenyl)-2,5-dimethoxyphenyl)diazenyl)-3-methoxyphenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 189-190 °C, MS (ESI) m / z 592 [M+H] + , 1H NMR (400 MHz, DMSO-d6) δ 8.49 (s, 2H), 7.65 (d, J = 9.38 Hz, 1H), 7.37 (s, 1H), 7.31 (s, 1H), 6.53 (d, J = 7.61 Hz, 1H), 6.40 (s, 1H), 4.0-3.94 (m, 6H), 3.92 (s, 3H), 3.69-3.59 (m,8H).
[0060] Example 10 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-hydroxyphenyl)azanediyl)bis(ethan-1-ol) (10) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S2 (R3=OH, R4=H) in ACN was slowly added at 0°C. After addition, the reaction mixture was stirred at 0°C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to obtain the product 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-hydroxyphenyl)azanediyl)bis(ethan-1-ol) as a purple solid. MP= 203-204°C, MS (ESI) m / z 551[M+H] +, 1H NMR (400 MHz, DMSO-d6) δ 8.47 - 8.40 (m, 2H), 8.09 - 8.03 (m, 2H), 7.62 (d, J = 9.3 Hz, 1H), 7.44 (s, 1H), 7.28 (s, 1H), 6.48 (dd, J = 9.4, 2.5 Hz, 1H), 6.40 (d, J = 2.5 Hz, 1H), 5.03 - 4.80 (m, 2H), 3.99 (s, 3H), 3.97 (s, 3H), 3.68 - 3.57 (m, 8H).
[0061] Example 11 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methoxyphenyl)amino)ethoxy)-4-oxobutanoic acid (11) To a stirred mixture of salt of S1 in a solution of NaOAc buffer and ACN (1:1), a solution of compound S4 (R4=H, R3=OCH3) in ACN was slowly added at 0°C. After addition, the reaction mixture was stirred at 0°C for 30 min. Completion of the reaction was monitored by TLC. The reaction mixture was then filtered and washed with ACN and water (1:1) to give 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methoxyphenyl)amino)ethoxy)-4-oxobutanoic acid as a purple solid. MP = 208-209°C, MS (ESI) m / z 927 [M+H] +, 1H NMR (400 MHz, DMSO-d6) δ 12.1 (brs, 1H), 8.44 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 7.59-7.57 (m, 1H), 7.44 (s, 1H), 7.36-7.34 (m, 2H), 7.28-7.20 (m, 7H), 7.08 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 9.2 Hz, 4H), 6.47-6.45 (m, 1H), 6.17-6.22-6.20 (m, 1H), 4.29-4.27 (m, 2H), 3.99-3.94 (m, 9H), 3.83-3.68 (m, 10H), 3.28-3.25 (m, 2H), 2.52-2.41 (m, 4H).
[0062] Photophysical testing of compounds of general formula I The photophysical properties of all synthesized compounds 1-6 were examined by UV-vis absorption analysis. Table 1 shows the absorption maxima and extinction ranges in PCR buffer (pH 7.2). Table 1. Photophysical properties of Examples 1-9 [Table 1]
[0063] All of the synthesized quenchers shown in the representative Examples 1 to 9 showed broad absorption spectra in PCR buffer at room temperature. The absorption spectra of the newly synthesized quencher derivatives (1 to 9) are shown in Figure 1. Among them, compounds 1 and 2 showed good intensity of absorption in the range of 400 to 750 nm. Similarly, when the methylene units of the alkoxy group in general formula I (R4 = H, R3 = OC1 to C6) were increased, a decrease in intensity was observed (Figure 1).
[0064] Comparison of the known quencher BHQ-2 with the novel quencher CDRI-Q2 of the present invention The absorption of the quencher CDRI-Q2 of the present invention (Example 1) was compared with the absorption spectrum of the known commercially available quencher BHQ-2. The data suggested that the quencher CDRI-Q2 of the present invention exhibited broader absorption and better intensity compared to BHQ-2 (Figure 2).
[0065] Quenching studies of CDRI-Q2 in the presence of various fluorescent dyes The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye 5-FAM, which has an emission maximum at 517 nm in PCR buffer (Figure 3).
[0066] The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye Cy-3, which has an emission maximum at 566 nm in PCR buffer (Figure 4).
[0067] The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye 5-TAMRA, which has an emission maximum at 583 nm in PCR buffer (FIG. 5).
[0068] The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye CalFluor red, which has an emission maximum at 601 nm in PCR buffer (FIG. 6).
[0069] The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye Texas Red, which has an emission maximum at 603 nm in PCR buffer (Figure 7).
[0070] The compound of the present invention, CDRI-Q2, was shown to effectively quench the fluorescent dye Cy-5, which has an emission maximum at 662 nm in PCR buffer (Figure 8).
[0071] Synthesis of dual-labeled probes A mixture of a fluorescent quencher of formula I containing an acid at the terminal (3 equiv.), DMAP (0.05 equiv.), triethylamine (13 equiv.), DEC / EDC (10 equiv.) and anhydrous pyridine (2 mL) was added to Controlled Pore Glass (CPG beads, 1000 A) containing a free amine, and then shaken at room temperature for 24 hours. The solvent was removed by suction filtration, washed with pyridine and DCM in turn, and dried under vacuum for several hours. The coupling efficiency was then determined using the detritylation method.
[0072] Labeling of 3'-quencher tagged oligonucleotides with fluorescent dyes at the 5'-end: Probes for RT-PCR-based diagnosis of COVID-19 were generated. CPG-amine (1000 Angs) was tagged with a representative novel quencher CDRI Q2 of general formula I. Oligonucleotide synthesis was performed as shown above using CPG-CDRI-Q2. Oligonucleotide sequences corresponding to different genes E and RdRp of one host and two viruses are shown in Table 2 (but are not limited to these viral genes). Using phosphoramidite-based solid-phase synthesis, a hexynyl group was introduced at the 5'-end of each 3'-CDRI Q2 tagged oligonucleotide using hexynyl phosphoramidite. Fluorescent dye azides were used, both commercially available and synthesized in-house.
[0073] Table 2: Oligonucleotide sequences of probes for RNaseP (host) and viral E and RdRP genes [Table 2]
[0074] A fluorescent dye azide was attached to hexynyl-oligonucleotide-3'-CDRI Q2 by copper(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition, also known as copper-catalyzed alkyne azide cycloaddition (CuAAC). The copper catalysis allows the specific synthesis of 1,4-disubstituted regioisomers.
[0075] Advantages of using fluorescent dye azides instead of fluorescent dye phosphoramidites Typically, dual-labeled probes are prepared by attaching fluorescent dyes to the 5'-end of oligonucleotides bearing a 3'-quencher using phosphoramidite chemistry. These fluorescent dye phosphoramidites are stored at -20°C, are unstable at room temperature, and are sensitive to moisture. In the present invention, fluorescent dye azides, which are stable at room temperature and essentially non-hygroscopic, were used. Such triazole-based dual-labeled oligonucleotides with different viral gene sequences (E gene, RdRp, and human gene RNaseP) have not been used to detect SARS-Cov2 or related virus infections using RTPCR technology. The results of triplex RT-PCR experiments are shown in Figures 9-11 of the drawings attached to the specification. Details of the different fluorescent dye azides used for labeling are shown in Table 3.
[0076] Table 3: Photophysical properties of different fluorescent dye azides [Table 3]
[0077] The reagents and stock solution concentrations used for the conjugation chemistry are shown in Table 4. [Table 4]
[0078] 500 μM stock solutions of 5′ modified oligonucleotides were prepared in nuclease free water (NFW) (Sigma Cat no) and 10 mM stock solutions of fluorescent dyes were prepared in molecular biology grade DMSO (Sigma).
[0079] For 100 μL of CuAAC reaction, a 50 μM alkyned oligo solution (10 μL from a 500 μM stock solution in NFW) was treated in sequence with 0.2 M triethylammonium acetate buffer, pH 7.0 (Sigma), followed by the addition of 50 μL of DMSO. The reaction mixture was mixed thoroughly by vortexing. A 150 μM fluorescent dye azide solution (1.5 μL from a 10 mM stock solution in DMSO) and a freshly prepared 0.5 mM ascorbic acid solution in NFW were further added to the reaction mixture, with thorough mixing after each reagent addition. The reaction mixture was then thoroughly degassed and flushed with argon for approximately 60 s. 0.5 mM copper(II)-tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine complex (Cu-TBTA complex, prepared by mixing 5 mg / mL copper(II) sulfate pentahydrate and 10.5 mg / mL TBTA in 55% DMSO) was added to the reaction mixture, mixed thoroughly by vortexing, and flushed with argon for an additional 60–100 s. The reaction mixture was incubated at 22°C for 12–16 h. After completion of the reaction, it was precipitated by adding 3 volumes of cold acetone and stored at -20°C for 30 min. The labeled DNA was extracted by high-speed centrifugation of the mixture at 10,000 rpm for 20 min at 4°C.
[0080] The pellet obtained in this step was washed twice with cold acetone (1 mL). The pellet obtained after the final wash was dried by further incubating the tube for about 30 min at 22° C. The dried fluorescent dye-labeled oligonucleotide obtained in this step was resuspended in 45 μL of cold NFW for HPLC purification.
[0081] Analytical purification of the labeled oligonucleotides was performed by HPLC using an XTerra MS C18 column (75 x 4.6 mm, packed with 2.5 μm particles, average pore size 125 Å) with an Inertsil C4 5 μm guard column (4.0 x 10 mm), a 20 μL sample loop, a dual-pump Shimadzu HPLC system equipped with an RF-20A spectrofluorimeter and an SPD-10A UV-VIS detector. The fluorescence detector was set to excitation and emission wavelengths corresponding to the fluorochromes of interest, and the UV detector was set to wavelengths of 260 nm and 280 nm. The mobile phase consisted of 0.1 M triethylammonium acetate buffer (pH 7.0, Sigma) and acetonitrile (HPLC grade, Sigma). A gradient of 0–60% acetonitrile over 30 min was applied to the column at a flow rate of 1 mL / min to separate the oligos. Peaks corresponding to both fluorescence and UV detection were manually collected and stored at -20°C. These stored samples were frozen in liquid nitrogen and lyophilized in a CHRiST freeze-drying system at 0.08 mbar and −51° C. The lyophilized probes were stored at −20° C. and used in RT-PCR to detect each gene.
[0082] Demonstration of the application of quenchers in RT-PCR-based diagnostic methods for SARS Cov-2 infection Assay Method 1) Extract RNA using a commercial kit. In the RT-PCR reaction, the first strand synthesis of cDNA from the RNA molecules is performed in one tube by RT-mix, followed by PCR amplification and detection using a specific primer-probe. Depending on the amount of target RNA present, template concentrations can range from 0.5 pg to 0.5 μg. Alternatively, this reaction can be performed separately with cDNA synthesis (0.5 μg to 2 μg). The cDNA can be diluted 3-5 times and used for PCR amplification and detection using a specific primer-probe; 2) The setup and cycling protocol of the real-time PCR reaction should follow the manufacturer's protocol. The concentrations of primers (forward and reverse) and probe can range from 0.2 μM to 1 μM; and 3) The fluorochrome-quencher is compatible with the detection of target genes in various real-time PCR instruments (ABI, BioRad) using channels specific for the fluorochromes.
[0083] FIG. 9 shows RT-PCR data with cycle threshold (Ct) on the X-axis and RFU on the Y-axis. FAM-RnaseP-BHQ1 (IDT) was used as a positive control. The probes used for detection were CDRI-Q2 at the 3' end and FAM / Texas Red (TR) / Cy5 at the 5' end. The data demonstrated the suitability of CDRI-Q2 for quenching in various ranges (520 nm to 670 nm) for accurate RT-PCR detection.
[0084] Multiplex RT-PCR detection of SARS-CoV-2 viral genes E and RdRp and RnaseP as housekeeping gene was performed with positive controls; data are shown in Figure 10 with cycle threshold (Ct) on the X-axis and RFU on the Y-axis. Data are shown in Figure 10 with cycle threshold (Ct) on the X-axis and RFU on the Y-axis. The data demonstrated the quenching compatibility of CDRI-Q2 in different emission ranges (450 nm to 700 nm) of RT-PCR.
[0085] Figure 11 also shows multiplex RT-PCR detection of SARS-CoV-2 viral genes E and RdRp and RnaseP as a housekeeping gene using positive RNA samples from COVID-19 positive patients; data shows cycle threshold (Ct) on the X-axis and RFU on the Y-axis. FAM-E-CDRI-Q2, TR-RdRp-CDRI-Q2 and Cy5-RnaseP-CDRI-Q2 probes were used. The data demonstrated the quenching compatibility of CDRI-Q2 in various emission ranges (450 nm-700 nm) of RT-PCR.
[0086] Advantages of the Invention The present invention provides a family of non-fluorescent quenchers with superior excited state energies, which are well-defined modifications of the known BHQ-2 ("black hole quencher"). According to the literature, BHQ-2 is suitable for dyes that emit in the orange to red portion of the visible range (560-670 nm), but not for FAM. For FAM, BHQ-1 is preferably used. The present invention provides a universal class of quenchers that are functionalized to allow rapid attachment to probe moieties, and also provides quenchers designed to have the desired broad quenching range covering the entire visible spectrum. The present invention describes the use of azides of fluorescent dyes that are stable at room temperature and essentially non-hygroscopic.
[0087] Quenchers may be composed of electron donating and electron withdrawing groups linked by a π-conjugated network. By modifying the conjugated system of the quencher and / or incorporating electron donating and withdrawing groups on the aromatic backbone, the spectral properties (e.g., absorbance) can be "tuned" to match the spectral properties (e.g., emission) of one or more fluorescent dyes. The novel quenchers of the present invention have demonstrated a broad range of absorption spectra covering the entire visible color gamut. These quenchers can be used to quench a variety of fluorescent dyes that emit in the 500-750 nm range, such as FAM, cyanine dyes, Texas Red, Calfluor red and other fluorescent dyes. In addition, they have better quenching properties (e.g., higher absorbance) than other well-known BHQ dyes.
Claims
1. General formula I: 【Chemistry 1】 [In the formula, R is independently selected from the group consisting of hydrogen and halogen; R 1 and R 2 is hydrogen, substituted or unsubstituted (C 1 -C 4 ) alkyl and (C 1 -C 6 ) alkoxy; R 3 is hydroxy, halogen, (C 1 -C 6 )alkoxy, substituted or unsubstituted (C 1 -C 4 ) Alkyl, thioalkyl (SC 1 -C 6 ), methylamino and dimethylamino; R 4 is hydrogen, hydroxy, halogen, (C 1 -C 6 )alkoxy and substituted or unsubstituted (C 1 -C 4 ) alkyl; m and n are independently selected from 0 to 3; Y 1 and Y 2 is hydrogen, (C 1 -C 6 ) independently selected from the group consisting of alkyl, glycol, substituted or unsubstituted alkylaryl, oxoalkanoic acid, epoxy, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, acid halide, acylimidazole, thioester, p-nitrophenyl ester, alkyl ester, phosphoramidite, mononucleotide unit, and two or more mononucleotide units with or without separate phosphate or polyphosphate groups linked by a nucleoside group. and nucleic acid conjugates, complexes and salts thereof.
2. The following compound: i. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methoxyphenyl)azanediyl)bis(ethan-1-ol) (1); ii. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-ethoxyphenyl)azanediyl)bis(ethan-1-ol) (2); iii. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-propoxyphenyl)azanediyl)bis(ethan-1-ol) (3); iv. 2,2'-((3-butoxy-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) (4); v. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-(hexyloxy)phenyl)azanediyl)bis(ethan-1-ol) (5); vi. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methylphenyl)azanediyl)bis(ethan-1-ol) (6); vii. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-2,5-dimethoxyphenyl)azanediyl)bis(ethan-1-ol) (7); viii. 2,2'-((3-bromo-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)azanediyl)bis(ethan-1-ol) (8); ix. 2,2'-((4-((4-((2,6-dichloro-4-nitrophenyl)diazenyl)-2,5-dimethoxyphenyl)diazenyl)-3-methoxyphenyl)azanediyl)bis(ethan-1-ol) (9); x. 2,2'-((4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-hydroxyphenyl)azanediyl)bis(ethan-1-ol) (10); xi. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methoxyphenyl)amino)ethoxy)-4-oxobutanoic acid (11); xii. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-ethoxyphenyl)amino)ethoxy)-4-oxobutanoic acid (12); xiii. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-propoxyphenyl)amino)ethoxy)-4-oxobutanoic acid (13); xiv. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(3-butoxy-4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)phenyl)amino)-ethoxy)-4-oxobutanoic acid (14); xv. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-(hexyloxy)phenyl)amino)-ethoxy)-4-oxobutanoic acid (15); and xvi. 4-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(4-((2,5-dimethoxy-4-((4-nitrophenyl)diazenyl)phenyl)diazenyl)-3-methylphenyl)amino)-ethoxy)-4-oxobutanoic acid (16), 2. The compound of claim 1, selected from the group consisting of:
3. The compound of claim 1, wherein the nucleic acid conjugate comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-3.
4. General formula I: 【Chemistry 2】 [In the formula, R is selected from the group consisting of hydrogen and halogen; R 1 and R 2 is hydrogen, substituted or unsubstituted (C 1 -C 4 ) alkyl and (C 1 -C 6 ) alkoxy; R 3 is hydroxy, halogen, (C 1 -C 6 )alkoxy, substituted or unsubstituted (C 1 -C 4 ) Alkyl, thioalkyl (SC 1 -C 6 ), methylamino and dimethylamino; R 4 is hydrogen, hydroxy, halogen, (C 1 -C 6 )alkoxy and substituted or unsubstituted (C 1 -C 4 ) alkyl; m and n are independently selected from 0 to 3; Y 1 and Y 2 is hydrogen, (C 1 -C 6 ) independently selected from the group consisting of alkyl, glycol, substituted or unsubstituted alkylaryl, oxoalkanoic acid, epoxy, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, acid halide, acylimidazole, thioester, p-nitrophenyl ester, alkyl ester, alkenyl ester, alkynyl ester, aromatic ester, phosphoramidite, mononucleotide unit, and two or more mononucleotide units with or without separate phosphate or polyphosphate groups linked by a nucleoside group. A method for producing the compound of formula (I) and its nucleic acid conjugates, complexes and salts, comprising the steps of: 【Chemistry 3】 a. reacting a solution of unsubstituted or substituted 4-nitroaniline in HCl with a solution of sodium nitrite in distilled water to form a diazonium salt which is then reacted with a substituted aniline to form a compound having the general formula S1; b. reacting the substituted aniline mixture with a substituted alkyl halide in the presence of a base to form a compound having the general formula S2; c. reacting a compound having general formula S1 in HCl with sodium nitrite solution to form a diazonium salt, which is then reacted with a compound having general formula S2 in the presence of NaOAc buffer to obtain a compound having general formula I; and d. isolating the compound of formula I from the reaction mixture and purifying it by washing with an organic solvent or by chromatography; A manufacturing method comprising:
5. Steps a to c are CH 3 The process according to claim 4, which is carried out in the presence of an organic solvent selected from CN, dimethylsulfoxide, water and tetrahydrofuran at a temperature ranging from 0 to 100°C for 1 minute to 3 days.
6. The method comprises the steps of: 【Chemistry 4】 a) Compound S2 (Y 1 , Y 2 =OH and m, n=1) with DMT-Cl in the presence of a base (DIPEA) at room temperature under an inert atmosphere to obtain compound S3; b) reacting S3 with succinic anhydride and DMAP in an organic solvent for 12-48 hours to give compound S4; and c) reacting the diazonium salt of S1 with S4 to obtain a compound having general formula I; 4. The method of claim 3, comprising:
7. A method for preparing a conjugate compound of general formula I, wherein Q is a quenching compound of formula 1, comprising the steps of: 【Chemistry 5】 a. coupling a compound of formula S4 with an amine functional group of a solid support CPG bead of formula S5 to generate S6, followed by deprotection of the DMT group to obtain S7; b. reacting S7 with a nucleotide phosphoramidite to form oligonucleotide S8, which is then 5'-modified with a hexynyl phosphoramidite to give product S9; c. treating S9 with a base to cleave the oligonucleotide from the solid support to obtain S10; and d. reacting S10 with an azide of a fluorescent dye to obtain an oligonucleotide probe of general formula S12; A manufacturing method comprising:
8. 2. The compound of claim 1, wherein the compound is used in combination with an acetyl, azide, oxoalkanoic acid, epoxy, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, acid halide, acylimidazole, thioester, p-nitrophenyl ester, alkyl ester, phosphoramidite, mononucleotide unit, two or more mononucleotide units with or without separate phosphate or polyphosphate groups linked by a nucleoside group.
9. 2. A method of detecting nucleic acids (DNA, RNA), peptides, chemicals, pharmaceuticals, microorganisms and other biological substances of diagnostic importance using the compounds of claim 1.
10. 2. A method for detecting substances, hormones, pathogenic microorganisms, viruses, antibodies, enzymes and nucleic acids using the compounds of claim 1.
11. The compound according to claim 1, which is useful for preparing single or dual labeled probes and analyzing them in single, dual and multiplex RT-PCR or other related detection systems.
Citation Information
Patent Citations
Process for diazotising aromatic amines
GB809350A
Novel substituted-polyaryl chromophoric compounds
US20040013375A1
Non-fluorescent quencher compounds and biomolecular assays
US8637658B2
Dark quenchers for donor-acceptor energy transfer
WO2001086001A1
Multi-chromophoric quencher constructs for use in high sensitivity energy transfer probes
WO2006031851A1
